7 April 2016Americas

DLA Piper adds partner and chair of FDA group

Law firm DLA Piper has hired James Czaban as a partner in the firm’s government affairs practice and chair of the firm’s US Food and Drug Administration group in Washington, DC.

Czaban joins from law firm Wiley Rein and has experience in compliance matters and Hatch-Waxman amendments to the Federal Food, Drug, and Cosmetic Act. He also has experience in licensing and regulatory due diligence.

Benjamin Boyd, co-managing partner of the firm’s Washington, DC office, said: “Jim’s extensive, multi-disciplinary regulatory experience will allow us to build upon our strong capabilities in the pharmaceutical, medical device, life sciences, food, and healthcare industries.

“He will be a great addition to our DC office, a great resource for our clients around the world, and we couldn’t be more pleased to have him on board,” he added.


More on this story

Americas
29 July 2014   DLA Piper has appointed life sciences lawyer Shane Albright to its corporate and finance practice.
Americas
14 September 2017   The Food and Drugs Administration has cleared the backlog of orphan drug designation requests, one month early.
article
2 October 2017   Canada has a robust and reliable framework for resolving IP disputes, and it shouldn’t be ignored by litigants, say Ron Dimock, Sangeetha Punniyamoorthy and Nikolas Purcell of DLA Piper.

More on this story

Americas
29 July 2014   DLA Piper has appointed life sciences lawyer Shane Albright to its corporate and finance practice.
Americas
14 September 2017   The Food and Drugs Administration has cleared the backlog of orphan drug designation requests, one month early.
article
2 October 2017   Canada has a robust and reliable framework for resolving IP disputes, and it shouldn’t be ignored by litigants, say Ron Dimock, Sangeetha Punniyamoorthy and Nikolas Purcell of DLA Piper.